COVID‐19 in a melanoma patient under treatment with checkpoint inhibition
Paul Schmidle, Tilo Biedermann, Christian Posch
Abstract
Editor, SARS-CoV-2 poses new challenges in all aspects of health care. 1 Patients with pre-existing cardiovascular conditions are at higher risk of developing severe symptoms and worse outcome. 2 Data also suggest that patients with cancer are particularly vulnerable, 2,3 but differences between tumour entities and cancer treatments may exist. Little is known how cancer treatment engaging immune checkpoints affects the course of COVID-19.
Topics & Concepts
MedicineNivolumabSore throatMelanomaInternal medicineCancerPembrolizumabImmunotherapyDiseaseAdjuvantSurgeryCancer researchCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchCancer Immunotherapy and Biomarkers